GE2270A
Also known as: Amythiamicin related, EF-Tu inhibitor peptide
Overview
GE2270A is a thiopeptide antibiotic produced by Planobispora rosea that inhibits bacterial translation by targeting elongation factor Tu (EF-Tu). It represents a structurally distinct class of antimicrobial peptides with a unique bacterial ribosome mechanism. While its poor aqueous solubility has historically limited development, GE2270A and related thiopeptides serve as important pharmacological tools for studying bacterial protein synthesis and as templates for next-generation antibiotics targeting the EF-Tu pathway.
Mechanism of Action
GE2270A binds with high affinity to the GTP-binding domain of bacterial elongation factor Tu (EF-Tu), preventing it from delivering aminoacyl-tRNAs to the ribosomal A-site. Without functional EF-Tu, bacterial ribosomes cannot elongate polypeptide chains, halting protein synthesis. This mechanism is entirely distinct from beta-lactam, aminoglycoside, and fluoroquinolone antibiotics, making GE2270A active against many multi-drug resistant strains. Mammalian EF-1α has different structural features, conferring selectivity.
Potential Benefits
- Activity against gram-positive multi-drug resistant pathogens
- Unique EF-Tu mechanism avoids cross-resistance with conventional antibiotics
- Research tool for studying bacterial translation
- Template for novel antibiotic development
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Not clinically available |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | N/A |
Thiopeptide antibiotic. Analogs (LFF571) progressed to Phase II for C. difficile — development halted.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (research LFF571 analog) Low systemic — concentrated in gut lumen
Intended for C. difficile — GI-localized action.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving GE2270A:
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store capsules/tablets at room temperature in a dry, dark place. Liquid formulations refrigerated. |
|---|
Oral peptide — no reconstitution required. Follow product label for storage specifics.
Need exact syringe measurements?
Amino Acid Sequence
Complex thiopeptide macrocycle (not standard linear peptide)
Side Effects & Safety
- Poor systemic bioavailability limits toxicity assessment
- Potential GI effects
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside GE2270A for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.